Adverse event ‐ Reduction in plasma cortisol below lower reference limit · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide 10 mg changes adverse event ‐ Reduction in plasma cortisol below lower reference… compared with prednisolone 40 mg (very low certainty).
1 finding from 1 review
Study Withdrawals · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide 10 mg changes study withdrawals compared with prednisolone 40 mg (very low certainty).
1 finding from 1 review
Clinical improvement · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in clinical improvement compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide 10 mg changes withdrawal due to adverse event compared with prednisolone 40 mg (very low certainty).
1 finding from 1 review
Clinical remission · Adult patients with active ulcerative colitis
Budesonide probably leads to lower clinical remission (ITT analysis) compared with mesalamine (moderate certainty).
1 finding from 1 review
Endoscopic improvement (dichotomous) · Adult patients with active ulcerative colitis
Budesonide probably leads to lower endoscopic improvement Gross 2011 compared with mesalamine (moderate certainty).
1 finding from 1 review
Endoscopic remission · Adult patients with active ulcerative colitis
Budesonide showed no clear difference in endoscopic remission (EI ≤ 1) compared with mesalamine (moderate certainty).
1 finding from 1 review
Histologic remission · Adult patients with active ulcerative colitis
Budesonide probably leads to lower histologic remission Gross 2011 compared with mesalamine (moderate certainty).
1 finding from 1 review
Adverse events Gross 2011 · Adult patients with active ulcerative colitis
Budesonide showed no clear difference in adverse events Gross 2011 compared with mesalamine (moderate certainty).
1 finding from 1 review
Remission (combined clinical and endoscopic remission) · Adult patients with active ulcerative colitis
Budesonide showed no clear difference in remission (combined clinical and endoscopic remission) compared with mesalamine (low certainty).
1 finding from 1 review
Clinical improvement · Adult patients with active ulcerative colitis
Budesonide showed no clear difference in clinical improvement compared with mesalamine (moderate certainty).
1 finding from 1 review
Serious adverse events · Adult patients with active ulcerative colitis
Budesonide showed no clear difference in serious adverse events compared with mesalamine (low certainty).
1 finding from 1 review
Remission (combined clinical and endoscopic remission) · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in remission (combined clinical and endoscopic remission) compared with entocort EC 9mg (low certainty).
1 finding from 1 review
Endoscopic improvement (dichotomous) · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg probably leads to higher endoscopic improvement compared with placebo (moderate certainty).
1 finding from 1 review
Clinical improvement · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in clinical improvement compared with entocort EC 9mg (moderate certainty).
1 finding from 1 review
Endoscopic improvement (dichotomous) · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in endoscopic improvement compared with entocort EC 9mg (moderate certainty).
1 finding from 1 review
Histologic remission · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in histologic remission compared with entocort EC 9mg (low certainty).
1 finding from 1 review
Serious adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with entocort EC 9mg (low certainty).
1 finding from 1 review
Adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in adverse events compared with entocort EC 9mg (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in withdrawal due to adverse events compared with entocort EC 9mg (moderate certainty).
1 finding from 1 review